Immunology drug Dupixent is seeing very strong, steady growth in atopic dermatitis and asthma, and approvals continue to expend to new indications (nasal polyposis) and younger patients.

13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab ...

Regeneron announced Friday that the company won Food and Drug Administration approval for Dupixent in chronic obstructive ...

2025 Oscar nominations predictions: See contenders for Best Picture and acting, from Angelina Jolie to Colman Domingo Angelina Jolie transforms in weird, whimsical, haunting trailer for new ...

The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease ...

Sanofi and Regeneron have reported positive interim data from the Phase III NOTUS trial with Dupixent (dupilumab) showing a 34% reduction in exacerbations in chronic obstructive pulmonary disease ...

Ebglyss' efficacy looks comparable, if not slightly superior, to current market leader Dupixent. Ebglyss has launched successfully in Germany and Japan, and I expect the launch in the U.S. to go ...

Dupixent is the leading biologic medicine for all five FDA-approved indications in new-to-brand prescriptions TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron ...

Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and ...